Published in Expert Rev Proteomics on April 01, 2008
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
The amyloid-beta peptide of Alzheimer's disease binds Cu(I) in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J Am Chem Soc (2008) 1.24
GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci (2014) 1.18
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Tau isoform composition influences rate and extent of filament formation. J Biol Chem (2012) 1.11
Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front Physiol (2012) 1.05
Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem. Front Neurol (2013) 0.96
Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis (2012) 0.96
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes (2012) 0.93
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep (2015) 0.91
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Regulation of human MAPT gene expression. Mol Neurodegener (2015) 0.90
An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem (2013) 0.90
Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci (2014) 0.89
MicroRNAs and the Regulation of Tau Metabolism. Int J Alzheimers Dis (2012) 0.89
Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci (2014) 0.87
From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans (2014) 0.85
The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study). Neurol Sci (2010) 0.84
Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. Proc Natl Acad Sci U S A (2014) 0.82
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry (2014) 0.81
Modeling the complex pathology of Alzheimer's disease in Drosophila. Exp Neurol (2015) 0.81
MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies. Acta Neuropathol Commun (2014) 0.81
TTBK2: a tau protein kinase beyond tau phosphorylation. Biomed Res Int (2015) 0.81
Treadmill exercise decreases incidence of Alzheimer's disease by suppressing glycogen synthase kinase-3β expression in streptozotocin-induced diabetic rats. J Exerc Rehabil (2015) 0.80
Antiproliferative factor-induced changes in phosphorylation and palmitoylation of cytoskeleton-associated protein-4 regulate its nuclear translocation and DNA binding. Int J Cell Biol (2012) 0.80
Cellular factors modulating the mechanism of tau protein aggregation. Cell Mol Life Sci (2015) 0.79
Tau deletion promotes brain insulin resistance. J Exp Med (2017) 0.78
Interaction of single and multi wall carbon nanotubes with the biological systems: tau protein and PC12 cells as targets. Sci Rep (2016) 0.78
Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review). Mol Med Rep (2015) 0.78
Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain (2016) 0.77
Ligand electronic properties modulate tau filament binding site density. Biophys Chem (2012) 0.77
Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro. J Proteome Res (2013) 0.77
Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. J Biol Chem (2014) 0.77
Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors. Bioorg Med Chem Lett (2011) 0.77
Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology (Berl) (2014) 0.76
Untangling tau imaging. Alzheimers Dement (Amst) (2016) 0.75
Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143-Further Implications for Alzheimer's Therapy. Front Neurosci (2017) 0.75
Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. Acta Neuropathol Commun (2017) 0.75
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology (2012) 2.87
Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain (2006) 2.71
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med (2009) 2.41
Poststroke dementia. Lancet Neurol (2005) 2.41
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science (2009) 2.35
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Electrosurgery and implantable electronic devices: review and implications for office-based procedures. Dermatol Surg (2011) 2.07
MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis (2008) 1.89
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet (2010) 1.83
Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain (2007) 1.76
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging (2007) 1.72
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem (2005) 1.68
Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis (2010) 1.65
Symptoms of B12 deficiency can occur in women of child bearing age supplemented with folate. Neurology (2002) 1.63
No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain (2007) 1.63
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis (2007) 1.54
The significance of cortical cerebellar microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis (2015) 1.53
Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol (2012) 1.49
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2010) 1.47
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology (2009) 1.43
C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain (2013) 1.42
Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci U S A (2005) 1.41
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem (2003) 1.40
Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J (2009) 1.40
Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem (2007) 1.35
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A (2007) 1.30
Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett (2002) 1.28
Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol (2007) 1.26
Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab (2002) 1.25
Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization. Biochim Biophys Acta (2003) 1.24
Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther (2009) 1.23
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res (2010) 1.22
Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta (2005) 1.21
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke (2007) 1.18
Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem (2003) 1.17
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis (2013) 1.16
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci (2005) 1.15
Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord (2004) 1.15
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol (2005) 1.14
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis (2010) 1.14
Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study. J Neurol Sci (2010) 1.13
Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res (2010) 1.13
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl (2003) 1.12
MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet (2011) 1.11
Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem (2003) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis (2008) 1.09
Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res (2008) 1.09
Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun (2014) 1.09
Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener (2012) 1.08
Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology (2005) 1.08
From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans (2010) 1.08
Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail (2007) 1.07
The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav (2003) 1.07
Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci (2012) 1.06